-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the introduction of proteasome inhibitors and immunomodulators , the prognosis of patients with multiple myeloma (MM) has been significantly improved, the remission rate has increased, and the progression-free survival (PFS) and overall survival (OS) are both significant Extend
.
It is now necessary to prospectively evaluate the effect of consolidation therapy on newly diagnosed patients with MM (TE-NDMM) eligible for transplantation
.
Recently, a new study (EMN02/HOVON95) published in the international journal "Journal of Clinical Oncology" evaluated the effect of consolidation therapy on such patients
.
The EMN02/HOVON95 trial recruited newly diagnosed TE-NDMM patients who were eligible for transplantation.
After induction and intensive treatment, two courses of consolidation therapy (bortezomib, lenalidomide, and dexamethasone [VRD]) were recruited.
Or not to give consolidation treatment, and then continue with nallidomide maintenance treatment
.
The primary endpoint is progression-free survival (PFS)
.
PFS of two groups of patients
PFS of two groups of patientsA total of 878 eligible patients were randomly divided into VRD consolidation group (451 patients) and non-consolidation group (427 patients)
.
After a median follow-up of 74.
8 months, patients in the VRD consolidation group had significantly longer median PFS adjusted for pretreatment (59.
The median PFS adjusted for preconditioning was significantly longer for patients in the VRD consolidation group .
Maintenance time of the two groups of patients
Maintenance time of the two groups of patientsThe median duration of remission was 33 months (interquartile range 13-86 months)
.
Median response duration is 33 months with a median duration of 33 months ≥ before maintenance therapy consolidation treatment vs non-consolidation complete remission (CR) rate of 34% vs 18% (P < 0.
OS of two groups of patients
OS of two groups of patientsTo sum up, the use of VRD for consolidation therapy and subsequent maintenance of lenalidomide can significantly improve the PFS and the depth of remission in patients with newly diagnosed multiple myeloma compared to maintenance therapy with lenalidomide alone
The use of VRD for consolidation therapy can significantly improve the PFS and the depth of remission in newly diagnosed multiple myeloma patients compared with the maintenance therapy of nallidomide.
Original source:
Pieter Sonneveld, et al.
Leave a message here
